Compare OBAI & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OBAI | NXL |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | N/A | 8 |
| Industry | Telecommunications Equipment | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3M | 10.2M |
| IPO Year | N/A | N/A |
| Metric | OBAI | NXL |
|---|---|---|
| Price | $1.03 | $0.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 17.1M | 810.7K |
| Earning Date | 05-27-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $15.52 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.43 | $0.31 |
| 52 Week High | $19.95 | $2.00 |
| Indicator | OBAI | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 68.91 | 40.14 |
| Support Level | $0.45 | $0.35 |
| Resistance Level | $1.66 | $0.48 |
| Average True Range (ATR) | 0.14 | 0.06 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 54.15 | 6.78 |
Our Bond Inc is a personal security service through its AI-powered Preventive Personal Security platform. It is trusted by corporations, cities, and universities, and has already supported many security service requests, emergencies and life-saving interventions. The cloud-based Bond Preventative Personal Security Platform provides users with remote protective services via phone app (using its Bond Preventative Personal Security Platform) and with 24/7 support from its Personal Security Agents, who are in Bond Command Centers and can respond rapidly. It offers distinct services through its phone app (the Bond App) and fully automated Bond Command Centers. Geographically, the company operates in Israel, France, and United States. It derives maximum revenue from United States.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.